Sana Biotechnology, Inc. (SANA): Total Assets
$416.89M
As of 2025-12-31
$431.52M
As of 2026-06-30
-20.3%
3-year compound annual growth
-10.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $416.89M | -16.8% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $501.02M | -11.4% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $565.30M | -31.3% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $822.72M | -27.2% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $1.13B | +54.7% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $730.30M | n/a | 2022-03-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $416.89M | -16.8% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $415.90M | -24.2% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $404.27M | -14.9% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $397.13M | +65.1% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $448.37M | -27.9% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $448.66M | +2.3% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $453.03M | -2.8% |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $464.13M | +224.8% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $364.98M | +292.7% |
Compare SANA, ALLO, SRRK, MAZE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗